Theravance Biopharma and Cumberland Pharmaceuticals Enter into $25 Million Antibiotic Deal

Specialty drugmaker Cumberland Pharmaceuticals will soon be adding a new antibiotic to its portfolio thanks to a $25 million deal it made with Theravance Biopharma. Cumberland has acquired Theravance’s Vibativ (telavancin), an FDA-approved antibiotic drug hospital-acquired and ventilator-associated bacterial pneumonia caused by Gram-positive pathogens.